Avita Medical (NASDAQ: RCEL) reported Q2 2026 revenue of $21.7M, up 18% YoY and 13% sequentially, driven by growth in its RECELL wound-care product and newer portfolio offerings. The upside pace suggests strengthening commercial momentum, though the update doesn’t provide margin or forward guidance detail.
Avita Medical (NASDAQ: RCEL) reported Q2 2026 revenue of $21.7M, up 18% YoY and 13% sequentially, driven by growth in its RECELL wound-care product and newer portfolio offerings. The upside pace suggests strengthening commercial momentum, though the update doesn’t provide margin or forward guidance detail.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
